[144] Xeris Biopharma Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) filed a Form 144 reporting a proposed sale of 42,232 common shares with an aggregate market value of $334,511.23. The filing shows the shares represent part of total outstanding common shares of 161,480,367 and names Morgan Stanley Smith Barney LLC as the broker on NASDAQ with an approximate sale date of 08/28/2025.

The securities were acquired and are being sold on 08/28/2025 via a stock option exercise from the issuer, with payment made in cash. The filer indicates there were no securities sold in the past three months to report and affirms no undisclosed material adverse information.

Positive

• Transparent disclosure of broker, sale date, and exact share count/value
• No sales reported in prior three months, suggesting this is an isolated liquidity event
• Acquisition and sale on same date via option exercise clarifies tax and reporting basis

Negative

• Insider sale of 42,232 shares may be perceived negatively by some investors despite small size relative to outstanding shares

Insights

Securities Analyst

TL;DR: Routine insider option exercise and proposed sale; size is modest relative to shares outstanding and appears non-material.

The Form 144 discloses a contemporaneous exercise and proposed sale of 42,232 shares valued at $334,511.23. Because the acquisition and proposed sale occur on the same date and payment is in cash, this aligns with common post-exercise liquidity events by insiders or option holders. Relative to total outstanding shares (161,480,367), the lot is economically small (~0.026%), suggesting limited market impact. The absence of reported sales in the prior three months reduces immediate concerns about an ongoing disposal pattern. For investors, this filing is informative about insider liquidity but not indicative of a material change to company fundamentals.

Compliance/Risk Analyst

TL;DR: Filing appears procedurally complete and includes required representations; no compliance red flags in disclosed fields.

The Form 144 includes required broker identification, sale timing, acquisition method, and a signature representation about lack of undisclosed material adverse information. The seller represents no material non-public information and notes no sales in the prior three months. The documentation of acquisition by stock option exercise and cash payment is clear. From a regulatory perspective, this notice meets standard disclosure elements for Rule 144 transactions; no explicit compliance issues are evident from the provided content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	42232	334511.23	161480367	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2025	Stock Option Exercise	Issuer			42232	08/28/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does XERS Form 144 disclose about the proposed sale?

The filing reports a proposed sale of 42,232 common shares valued at $334,511.23 with an approximate sale date of 08/28/2025 on NASDAQ.

How were the XERS shares acquired that are being sold?

The securities were acquired on 08/28/2025 via a stock option exercise from the issuer, with payment made in cash.

Who is the broker handling the sale in the XERS Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, New York, NY.

Does the filing indicate prior sales by the same person in the past three months?

The Form 144 states Nothing to Report for securities sold during the past three months.

How material is the sale compared with XERS outstanding shares?

The sale of 42,232 shares represents approximately 0.026% of the reported 161,480,367 shares outstanding, indicating limited size relative to the float.